Aristotle University Of Thessaloniki (AUTH)
Μελέτη με οπτική τομογραφία συνοχής του οιδήματος της ωχράς κηλίδας στην υποωχρική νεοαγγείωση μετά από ενδοϋαλοειδική ένεση αντιαγγειογενετικών παραγόντων
Abstract
dc:descriptionRelated Macular Degeneration ( AMD ) causes severe vision loss and is the leading cause of irreversible blindness among people who are 50 years of age or older in the developed world .Most patients suffer from the non-neovascular form of the disease , characterised by drusen , geographical atrophy and retinal pigment epitheli- um atrophy . 80-90% of severe vision loss from AMD is due to choroidal neovascu- larization. Although stimuli that promote the choroidal neovascularization is not entirely clear, there is evidence that constitute that VEGF (vascular endothelial growth factors) have a key role in the development of the neovascularization along with FGF2. Also the PEDF, ECM and angiopoietins seem to have a role. The properties of VEGF is as follows; 1. Activators of angiogenesis. 2. Strong agonists of vascular permeability. 3. Pre-inflammatory factors . 4. Neuroprotective factors ( neuroprotective action in situations of hypoxia , oxida- tive stress ). 5. Vascular survival factors .The purpose of this study is to evaluate the efficacy of intravitreal ranibizumab and bevacizumab injection as first line treatment in choroidal neovascularization due to AMD. The assessment will be done by studying the changes in Visual acuity (BCVA) and the thickness of the Central retina (CRT) before and after treatment . The granting of these two factors gives clinically and statistically significant and ac- ceptable results. According to our study; a) to both factors the average reduction of the central retinal thickness (CRT) after charging dose is equal to that at the end of follow up without significant differ- ence. More specifically, 60.12 µm after charging dose of ranibizumab and 69,18 µm at the end of followup. The corresponding figures for the bevacizumab is 43,82 µm and 48,88 µm. b) ranibizumab ; the greater proportion of the gain of the mean BCVA is completed after the charging dose and until the end of followup shows further improvement (logMAR and 0,3553 logMAR 0,2515 respectively) (12,57 and 17,76 EDTRS let- ters respectively ). c) bevacizumab ; the gain of the BCVA after the end of the charging dose seems to be almost the same as at the end of follow-up. (0,2441 and 0,2435 respectively logMAR ) (12,2 and 12,17 EDTRS letters respectively ). d) While both factors give a statistically significant result in the reduction of CRT patients cured with ranibizumab, quoting the results of the two groups seem to have a greater reduction in the CRT, borderline statistically significant, so after loading dose and at the end of followup.Loading dose: 60.12 µm ranibizumab-43,82 µm bevacizumab. End of followup: 48,88 69,18 µm ranibizumab-µm bevacizumab. e) Respectively for the BCVA the result after the charging dose seems to be equal ( 0,2515 logMAR ranibizumab 0,2441 logMAR bevacizumab )while at the end of followup there is slight superiority of ranibizumab (gain 0,2435 logMAR versus logMAR 0,3553),which is non-statistically significant. f) In our study we had no particular side effects . We didn’t observe serious oph- thalmological complications , they were limited to reported tingling in the affected eye and in the presence of subconjuctival haemorrhage (hyposphagma ).Also we didn’t observe serious systemic complications like vascular episodes ,myocardial infarction or CVA ( stroke ) .
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zampros, Ilias
- Ζάμπρος, Ηλίας
Subjects
dc:subject × 6Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/34649